Nautilus Biotechnology (NAUT) rose 11.11% in premarket trading, driven by news that Wall Street Zen upgraded the stock to "Hold" and Y Intercept Hong Kong Ltd. acquired a new position. Recent earnings reports and insider buying activity also signaled confidence in the company’s prospects. Other news events, including updates on a TV series and a neuroscience trial, pertained to unrelated entities and did not influence the stock’s movement.
Comments
No comments yet